ArticleClinical, cosmetic and investigational dermatology2026
Predictive Factors of Early Super-Response to Biologic Agents in Psoriasis: Insights from Real-World Evidence.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objectives: The concept of early super-response (ESR) in psoriasis, characterized by rapid and sustained complete skin clearance, has recently gained clinical relevance. However, evidence regarding predictors of ESR remains limited. This study aimed to identify clinical and laboratory factors associated with ESR in patients with psoriasis vulgaris treated with biologics. Methods: In this retrospective study, 299 patients with psoriasis vulgaris receiving biologic therapy were evaluated. ESR was defined as achieving a PASI 100 response at week 4 and maintaining PASI < 1 through week 48. Demographic, clinical, and laboratory parameters were compared between ESR and non-ESR groups. Variables with p < 0.1 in univariate analyses were entered into multivariate logistic regression to identify independent predictors. Results: Bio-naïve status (OR = 2.16, 95% CI 1.17-3.96, p = 0.013) and higher baseline neutrophil count (OR = 1.26, 95% CI 1.04-1.53, p = 0.016) were independent positive predictors of ESR, while palmoplantar involvement (OR = 0.27, 95% CI 0.13-0.58, p = 0.001) was a strong negative predictor. Smoking (OR = 0.57, 95% CI 0.29-1.11, p = 0.099) showed a borderline negative association, and platelet-to-lymphocyte ratio (PLR) (OR = 1.005, 95% CI 0.999-1.01, p = 0.083) demonstrated a borderline positive effect. At the biologic class level, no statistically significant differences in ESR rates were observed. Moreover, biologic class was not independently associated with ESR in multivariable analyses after adjustment for clinically relevant covariates. Conclusion: Bio-naïve status and elevated baseline neutrophil count predicted rapid and sustained complete clearance with biologic therapy, whereas palmoplantar involvement impaired early response. These findings emphasize the prognostic role of baseline inflammatory and phenotypic features in guiding personalized psoriasis management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.